Table 1 Biological properties of the thyroid-derived cell lines used in this study and their sensitivity to doxorubicin and RNases

						Antitumour agent IC₅₀^c
Cell line	Genetic lesion	Doubling time (h)	CFE^a	Tumour incidence^b	Latency	Dox.	BS	HHP2
In vitro transformed rat cells
FRTL-5		33	0	0		1.5	>500	>500
FRTL-5-v-src	v-src	28	20	85	3 weeks	40	100	250
FRTL-5-v-Ki-ras	v-Ki-ras	14	49	100	5 days	200	10	18
Tumour- and metastasis-derived rat cells
TK-6	v-Ki-ras	24	34	100	2.5 weeks	180	15	30
MPTK-6	v-Ki-ras	16	74	100	7–10 days	300	10	10
Human cells
P5	—	58	0	0	—	0.9	>500	>500
HDF	—	36	0	0	—	2	>500	>500
TPC1	ret/ptc1	26	1	0	—	5	140	320
Cal 62	p53^; N-ras*	24	20	100	7 days	Not done	74	37
NPA	p53−/−; B-raf^*	13	82	100	20 days	300	5	5
ARO	p53^*	10	92	100	4 days	280	60	61

^aColony-forming efficiency was measured in agar and calculated by the formula: (number of colonies formed/number of plated cells) × 100. Colonies larger than 64 cells were scored after 2–3 weeks.
^bTumorigenicity was assayed by injecting 10⁶ cells into either nude mice or syngenic rats. The incidence (%) was calculated as the per cent of animals with tumours over the total number of animals tested.
^cThe inhibiting concentration values (IC₅₀) were determined by the colony-forming assay and are expressed as nM concentrations. Values are means±s.d. of triplicate determinations from three independent experiments.
^*Presence of a mutated protein.

Quick links

Search